
Cosibelimab-ipdl is now an NCCN Category 2A option for locally advanced CSCC in patients ineligible for curative surgery or radiation.
Barcelona ?? The next time one of your female patients worries that her thinning hair will lead to baldness, you can reassure her that, most likely, it does not mean she is going bald. The same goes for women who are experiencing recession near her temples, a less common variety of hair loss.






